Protagonist Therapeutics Q3 revenue surges on Takeda payments
Protagonist Therapeutics Q3 revenue surges on Takeda payments
Overview
US biopharma firm's Q3 license and collaboration revenue surged on Takeda milestone and opt-out payments
Company swung to net income in Q3 from a loss a year earlier; diluted EPS turned positive
Company authorized $300 mln share buyback program
Outlook
Company expects R&D expenses to rise in late 2026 due to advancing clinical programs
Company plans to start Phase 2b study of PN-881 in plaque psoriasis in early Q1 2027
Company expects to begin Phase 1 study of oral PN-477o in H1 2027
Result Drivers
TAKEDA PAYMENTS - Q3 revenue primarily driven by $200 mln opt-out fee and $75 mln milestone from Takeda after FDA approval of MIMRYLO
R&D SPENDING - Higher R&D expenses mainly due to clinical and preclinical programs, partly offset by lower rusfertide trial costs
Company press release: ID:nACSrmDx0a
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q3 License and Collaboration Revenue |
| $274.41 mln |
|
Q3 EPS |
| $3.07 |
|
Q3 Net Income |
| $220.02 mln |
|
Q3 Income from Operations |
| $218.33 mln |
|
Q3 Operating Expenses |
| $56.08 mln |
|
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 15 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Protagonist Therapeutics, Inc. is $175.50, about 22.4% above its November 4 closing price of $143.37
The stock recently traded at 860 times the next 12-month earnings vs. a P/E of 95 three months ago
Reuters Recommended Reads
Nov 3 - Amgen Q3 revenue beats expectations on higher volumes
Nov 2 - Vertex Pharmaceuticals' Q3 revenue slightly beats estimates, outlook raised
Nov 3 - Amgen posts higher-than-expected third quarter results, but shares dip
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)
Recent news on Protagonist Therapeutics
See all newsProtagonist Therapeutics, Inc. reports results for the quarter ended September 30 - Earnings Summary
Protagonist Therapeutics Q3 revenue surges on Takeda payments
Brief: Protagonist Therapeutics Q3 EPS USD 3.07
UK approves J&J's oral psoriasis pill
U.S. RESEARCH ROUNDUP-Adobe, Braveheart Bio, CACI International